M42 said the new subsidiary, M42 Saudi Arabia, builds on more than 12 years of engagement in the Saudi market through its partnership with the Ministry of Health, including managing over 40 clinics in 33 cities under its Diaverum renal-care network. Under the new structure, M42 intends to expand beyond renal-care services and delve into multi-omics, population-health programmes, lifestyle-disease management, digital integration and clinical trials.
Group chief executive Dimitris Moulavasilis described the step as “a natural progression in building a globally scaled health-intelligence ecosystem in partnership with local institutions to shift from reactive care to precision, prevention and prediction.” Ziyad Kabli, chief operations officer for the Middle East and Asia at M42, said the business is moving from “specialty services to system-wide collaboration in advanced healthcare.”
Saudi officials view the move as highly synergistic with healthcare transformation plans. The Kingdom has placed technology-enabled health services and life-sciences investment at the centre of its strategy to build a future-ready system. M42 said its Saudi unit will support pilot programmes, research, and partnerships with both governmental and private healthcare providers.
M42 describes itself as a global leader powered by artificial intelligence, technology and genomics, operating across multiple platforms including global patient care, digital-health solutions, integrated health systems and AI-driven life sciences. Its establishment in Saudi Arabia anchors the group’s intent to deepen its footprint across the Middle East and participate in broader shifts from traditional care to value-based, digitally-enhanced systems.
Regional expansion by M42 has been gaining traction. In August 2025, its digital-health-solutions arm, Abu Dhabi Health Data Services, launched a virtual-hospital network dubbed the Jordan Digital Health Centre in Jordan. The initiative connected five remote hospitals to a central command centre in Al Salt and incorporated Tele-ICU, Tele-dialysis and Tele-radiology services, cutting diagnostic turnaround times from up to 14 days to under two. That operation underscores the technical capabilities M42 brings to the Saudi market and its model of public-private collaboration.
Analysts say the Saudi healthcare market is increasingly attractive for technology-enabled operators. With the market supported by government mandates to expand clinical trials, develop local life-sciences manufacturing and integrate digital health records nationwide, entry by an organisation like M42 signals heightened competition and potential for innovation. At the same time, local incumbents and regulatory frameworks will test the ability of global players to scale effectively in a system that emphasises national-capacity building.
Potential hurdles include ensuring seamless integration with existing care providers, data-governance standards for patient information, aligning with Saudi Arabia’s regulatory and cultural environment and securing local talent for advanced health-technology operations. Observers caution that execution risk remains significant in large-scale healthcare transformation projects, particularly when moving from single-service delivery to system-wide delivery models.
Topics
Live News